Kefort

Ibandronic acid, the active ingredient in Kefort, is a bisphosphonate presented as an oral tablet for oral use. It is used to treat osteoporosis in post‑menopausal women and men at risk of fractures.

GNH USA supplies Kefort as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kefort is a bisphosphonate indicated for conditions involving bone loss and fracture risk.

- Osteoporosis: helps reduce the risk of vertebral and non‑vertebral fractures by inhibiting bone resorption. - Post‑menopausal bone loss: improves bone mineral density in women after menopause. - Male osteoporosis: supports bone strength in men diagnosed with osteoporosis.

Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia. - Musculoskeletal pain: transient bone, joint, or muscle aches. - Headache: mild to moderate intensity. - Flu‑like symptoms: fever, chills, or fatigue. - Skin reactions: rash or pruritus.

Serious or Rare Side Effects: - Osteonecrosis of the jaw: persistent jaw pain or exposed bone. - Atypical femoral fractures: sudden thigh or groin pain. - Severe hypersensitivity: anaphylaxis or angioedema. - Renal impairment: sudden decrease in kidney function. - Electrolyte disturbances: low calcium or magnesium levels.

Before starting Kefort, consider the following precautions: - Renal function: assess kidney health and avoid use in severe impairment. - Calcium/vitamin D status: ensure adequate supplementation to reduce hypocalcemia risk. - Dental procedures: inform dentist of therapy; avoid invasive dental work when possible. - Concomitant medications: review use of NSAIDs, corticosteroids, or other bone‑active agents. - Pregnancy and lactation: avoid use unless clearly indicated by a physician. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Ibandronic acid may interact with several medicines.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption of ibandronate. - Calcium supplements: interfere with drug uptake if taken simultaneously. - Concomitant bisphosphonates: increase risk of cumulative toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase gastrointestinal irritation. - Corticosteroids: can exacerbate bone loss, requiring careful monitoring. - Diuretics (loop): may affect calcium balance and renal function.